222 related articles for article (PubMed ID: 32603560)
21. Medication augmentation after the failure of SSRIs for depression.
Trivedi MH; Fava M; Wisniewski SR; Thase ME; Quitkin F; Warden D; Ritz L; Nierenberg AA; Lebowitz BD; Biggs MM; Luther JF; Shores-Wilson K; Rush AJ;
N Engl J Med; 2006 Mar; 354(12):1243-52. PubMed ID: 16554526
[TBL] [Abstract][Full Text] [Related]
22. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
Simon JS; Nemeroff CB
J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
[TBL] [Abstract][Full Text] [Related]
23. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
Chen SJ; Hsiao YL; Shen TW; Chen ST
J Clin Psychopharmacol; 2012 Feb; 32(1):56-60. PubMed ID: 22198444
[TBL] [Abstract][Full Text] [Related]
24. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.
Jha MK; Minhajuddin A; South C; Rush AJ; Trivedi MH
Am J Psychiatry; 2019 May; 176(5):358-366. PubMed ID: 30922100
[TBL] [Abstract][Full Text] [Related]
25. Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial.
Zisook S; Moutier CY; Rush AJ; Johnson GR; Tal I; Chen PJ; Davis LL; Hicks PB; Wilcox J; Planeta B; Lauro KW; Scrymgeour AA; Kasckow J; Mohamed S
Psychol Med; 2024 Apr; 54(6):1172-1183. PubMed ID: 37859623
[TBL] [Abstract][Full Text] [Related]
26. What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study.
Rush AJ; South C; Jha MK; Jain SB; Trivedi MH
J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32780949
[TBL] [Abstract][Full Text] [Related]
27. Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History.
Buchalter ELF; Oughli HA; Lenze EJ; Dixon D; Miller JP; Blumberger DM; Karp JF; Reynolds CF; Mulsant BH
J Clin Psychiatry; 2019 Dec; 80(6):. PubMed ID: 31846575
[TBL] [Abstract][Full Text] [Related]
28. The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.
Bartova L; Fugger G; Dold M; Kautzky A; Swoboda MMM; Rujescu D; Zohar J; Souery D; Mendlewicz J; Montgomery S; Fabbri C; Serretti A; Kasper S
Int J Neuropsychopharmacol; 2022 Feb; 25(2):118-127. PubMed ID: 34637516
[TBL] [Abstract][Full Text] [Related]
29. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
Han C; Wang SM; Kwak KP; Won WY; Lee H; Chang CM; Tang TC; Pae CU
J Psychiatr Res; 2015; 66-67():84-94. PubMed ID: 26013203
[TBL] [Abstract][Full Text] [Related]
30. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
[TBL] [Abstract][Full Text] [Related]
31. An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants.
Youssef NA; Marx CE; Bradford DW; Zinn S; Hertzberg MA; Kilts JD; Naylor JC; Butterfield MI; Strauss JL
Int Clin Psychopharmacol; 2012 Jul; 27(4):191-6. PubMed ID: 22475888
[TBL] [Abstract][Full Text] [Related]
32. Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report.
Zisook S; Johnson GR; Hicks P; Chen P; Beresford T; Michalets JP; Rao S; Thase ME; Wilcox J; Sevilimedu V; Mohamed S
Depress Anxiety; 2021 Feb; 38(2):185-195. PubMed ID: 33225492
[TBL] [Abstract][Full Text] [Related]
33. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.
Cook IA; Hunter AM; Gilmer WS; Iosifescu DV; Zisook S; Burgoyne KS; Howland RH; Trivedi MH; Jain R; Greenwald S; Leuchter AF
J Clin Psychiatry; 2013 Jan; 74(1):51-6. PubMed ID: 23419226
[TBL] [Abstract][Full Text] [Related]
34. Quality of Life and Functioning in Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder After Treatment With Citalopram Monotherapy.
Steiner AJ; Boulos N; Mirocha J; Wright SM; Collison KL; IsHak WW
Clin Neuropharmacol; 2017; 40(1):16-23. PubMed ID: 27764051
[TBL] [Abstract][Full Text] [Related]
35. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression.
McCarthy MJ; Chen Y; Demodena A; Leckband SG; Fischer E; Golshan S; Suppes T; Kelsoe JR
J Psychopharmacol; 2021 Aug; 35(8):992-1002. PubMed ID: 33938307
[TBL] [Abstract][Full Text] [Related]
36. Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.
Gebara MA; DiNapoli EA; Kasckow J; Karp JF; Blumberger DM; Lenze EJ; Mulsant BH; Reynolds CF
Int J Geriatr Psychiatry; 2018 Feb; 33(2):e330-e335. PubMed ID: 28975710
[TBL] [Abstract][Full Text] [Related]
37. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
Oslin DW; Lynch KG; Shih MC; Ingram EP; Wray LO; Chapman SR; Kranzler HR; Gelernter J; Pyne JM; Stone A; DuVall SL; Lehmann LS; Thase ME; ; Aslam M; Batki SL; Bjork JM; Blow FC; Brenner LA; Chen P; Desai S; Dieperink EW; Fears SC; Fuller MA; Goodman CS; Graham DP; Haas GL; Hamner MB; Helstrom AW; Hurley RA; Icardi MS; Jurjus GJ; Kilbourne AM; Kreyenbuhl J; Lache DJ; Lieske SP; Lynch JA; Meyer LJ; Montalvo C; Muralidhar S; Ostacher MJ; Paschall GY; Pfeiffer PN; Prieto S; Przygodzki RM; Ranganathan M; Rodriguez-Suarez MM; Roggenkamp H; Schichman SA; Schneeweis JS; Simonetti JA; Steinhauer SR; Suppes T; Umbert MA; Vassy JL; Voora D; Wiechers IR; Wood AE
JAMA; 2022 Jul; 328(2):151-161. PubMed ID: 35819423
[TBL] [Abstract][Full Text] [Related]
38. Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
Uher R; Frey BN; Quilty LC; Rotzinger S; Blier P; Foster JA; Müller DJ; Ravindran AV; Soares CN; Turecki G; Parikh SV; Milev R; MacQueen G; Lam RW; Kennedy SH;
J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32558407
[TBL] [Abstract][Full Text] [Related]
39. Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Sung SC; Wisniewski SR; Luther JF; Trivedi MH; Rush AJ;
J Affect Disord; 2015 Mar; 174():157-64. PubMed ID: 25497473
[TBL] [Abstract][Full Text] [Related]
40. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
Jefferson JW; Rush AJ; Nelson JC; VanMeter SA; Krishen A; Hampton KD; Wightman DS; Modell JG
J Clin Psychiatry; 2006 Jun; 67(6):865-73. PubMed ID: 16848645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
